1H 2022: Growing Market Uncertainty
- The second quarter was defined by general sense of uncertainty in the market, as concerns about inflation and rising interest rates dominated headlines
- On top of the economic factors impacting the market, major geopolitical issues continue to add uncertainty. The conflict between Russia and Ukraine continues to shape geopolitical discourse, while periodic outbreaks of COVID apply strain on the healthcare system. Public equity markets reflected this negative sentiment with an underwhelming second quarter, but middle market M&A transactions have not been impacted to the same extent.
- Despite market concerns, 2022 Q2 M&A transaction volume remained strong, with a robust 28% increase from Q1. The total deal volume of 299 transactions for the first half of the year is higher than the 2017-2020 average. Activity levels can be attributed to record amounts of private equity dry powder and appetite for high quality assets that can perform in a volatile market.
- During the first half of the year, PMCF’s four tracked medical subsector indices all outperformed the benchmark S&P 500 Growth Index, which was down 28.5%, and two of the indices outperformed the Dow Jones Industrial Average, which was down 15.9%.
Read Medical Technology M&A Pulse Q2 2022 Full Report
Medical Technology M&A Pulse – Q2 2024
Ongoing volatility in the Medical Technology M&A sector is driving heightened diligence and investor scrutiny to ensure acquisition targets are high-quality assets capable of withstanding current market turbulence.
Medical Technology M&A Pulse – Q1 2024
Persistent inflation in Q1 2024 delayed expected rate cuts as the Federal Reserve back tracked expectations from four to three cuts this year.
Medical Technology M&A Pulse – Q4 2023
Concerns about a recession dominated economic discussions in early 2023, fueled by the Federal Reserve’s aggressive response to historically high inflation.
Medical Technology M&A Pulse – Q3 2023
Inflation, while still an economic focal point, is not the sentiment driver it was earlier in the year and in 2022.
Medical Technology M&A Pulse – Q2 2023
One year into an unprecedented cycle of interest rate increases, the task of an economic soft landing, once deemed nearly impossible, appears more and more likely.